Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 8/20 | 0.41 |
| ▸ | SRC | P12931 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30220574 | 0.82 | XDH (0.47) | XDHSYKABL1SRCGAA | |
| SCHEMBL20504460 | 0.82 | XDH (0.47) | XDHSYKABL1SRCGAA | |
| SCHEMBL6321559 | 0.76 | HRH4 (0.56) | XDHABL1SRCGAAGLA | |
| Hydrochloric Acid SCHEMBL6988299 | 0.75 | HRH4 (0.54) | XDHABL1SRCGAAGLA | |
| SCHEMBL1652997 | 0.73 | KDM4E (0.47) | ABL1SRCGAA | |
| SCHEMBL4271585 | 0.71 | HRH4 (0.57) | ABL1SRC | |
| SCHEMBL31088687 | 0.71 | HRH4 (0.57) | ABL1SRC | |
| SCHEMBL3283667 | 0.71 | NSD2 (0.61) | XDHABL1SRCGAAGLA | |
| SCHEMBL10509208 | 0.71 | XDH (0.50) | XDHABL1SRCGAAGLA | |
| SCHEMBL16402335 | 0.71 | MAPK1 (0.44) | XDHABL1SRCGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8957070-B2 | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-1873144-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1873144-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-2308839-A1 | Fused heterocyclic compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308839-A1 | Fused heterocyclic compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | XDH 558/4885SYK 1673/4885PTPN11 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.